WallStSmart

Chubb Ltd (CB)vsIntuitive Surgical Inc (ISRG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Chubb Ltd generates 492% more annual revenue ($59.63B vs $10.06B). ISRG leads profitability with a 28.4% profit margin vs 17.3%. ISRG appears more attractively valued with a PEG of 2.43. CB earns a higher WallStSmart Score of 69/100 (B-).

CB

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 7.0Value: 7.3Quality: 5.3
Piotroski: 4/9

ISRG

Buy

62

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 4.7Quality: 7.8
Piotroski: 4/9Altman Z: 6.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CBUndervalued (+73.1%)

Margin of Safety

+73.1%

Fair Value

$1202.76

Current Price

$323.21

$879.55 discount

UndervaluedFair: $1202.76Overvalued
ISRGSignificantly Overvalued (-78.8%)

Margin of Safety

-78.8%

Fair Value

$262.88

Current Price

$469.98

$207.10 premium

UndervaluedFair: $262.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CB6 strengths · Avg: 8.2/10
Market CapQuality
$126.41B9/10

Large-cap with strong market position

P/E RatioValuation
12.6x8/10

Attractively priced relative to earnings

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Operating MarginProfitability
24.2%8/10

Strong operational efficiency at 24.2%

EPS GrowthGrowth
27.9%8/10

Earnings expanding 27.9% YoY

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

ISRG5 strengths · Avg: 9.2/10
Operating MarginProfitability
30.2%10/10

Strong operational efficiency at 30.2%

Altman Z-ScoreHealth
6.1810/10

Safe zone — low bankruptcy risk

Market CapQuality
$167.61B9/10

Large-cap with strong market position

Profit MarginProfitability
28.4%9/10

Keeps 28 of every $100 in revenue as profit

Revenue GrowthGrowth
18.8%8/10

18.8% revenue growth

Areas to Watch

CB1 concerns · Avg: 2.0/10
PEG RatioValuation
2.862/10

Expensive relative to growth rate

ISRG3 concerns · Avg: 3.3/10
PEG RatioValuation
2.434/10

Expensive relative to growth rate

Price/BookValuation
9.4x4/10

Trading at 9.4x book value

P/E RatioValuation
59.9x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : CB

The strongest argument for CB centers on Market Cap, P/E Ratio, Price/Book. Profitability is solid with margins at 17.3% and operating margin at 24.2%.

Bull Case : ISRG

The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 28.4% and operating margin at 30.2%. Revenue growth of 18.8% demonstrates continued momentum.

Bear Case : CB

The primary concerns for CB are PEG Ratio.

Bear Case : ISRG

The primary concerns for ISRG are PEG Ratio, Price/Book, P/E Ratio. A P/E of 59.9x leaves little room for execution misses.

Key Dynamics to Monitor

CB profiles as a mature stock while ISRG is a growth play — different risk/reward profiles.

ISRG carries more volatility with a beta of 1.68 — expect wider price swings.

ISRG is growing revenue faster at 18.8% — sustainability is the question.

CB generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

CB scores higher overall (69/100 vs 62/100), backed by strong 17.3% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Chubb Ltd

FINANCIAL SERVICES · INSURANCE - PROPERTY & CASUALTY · USA

Chubb Limited, incorporated in Zurich, Switzerland, is the parent company of Chubb, a global provider of insurance products covering property and casualty, accident and health, reinsurance, and life insurance and the largest publicly traded property and casualty company in the world.

Intuitive Surgical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.

Want to dig deeper into these stocks?